Laurus Labs Quarterly Results
Laurus Labs quarterly results. In Mar 2026, Laurus Labs (LAURUSLABS) reported revenue ₹1,823 Cr and net profit ₹282 Cr — revenue +2.5% YoY. Review LAURUSLABS P/E comparison to evaluate earnings-based valuation against sector peers.
LAURUSLABS Quarterly Results — Revenue, Profit & EPS Highlights
Laurus Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit LAURUSLABS share price screener.
- Revenue of ₹1,823 Cr in Mar 2026 (-10.5% vs Jun 2026, +2.5% vs Mar 2025)
- Net Profit of ₹282 Cr in Mar 2026 (-22.1% vs Jun 2026, +21.0% vs Mar 2025)
- EBITDA of ₹524 Cr in Mar 2026 (-19.1% vs Jun 2026)
- Operating Margin of 28.0% in Mar 2026 (-4.0pp vs Jun 2026)
- Earnings Per Share of ₹5.17 in Mar 2026 (-24.1% vs Jun 2026)
Laurus Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LAURUSLABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,823 | 2,036 | 1,680 | 1,779 | 1,580 | -10.5% | 2.5% |
| Net Profit (₹ Cr) | 282 | 362 | 195 | 233 | 162 | - | - |
| EBITDA (₹ Cr) | 524 | 648 | 430 | 479 | 393 | - | - |
| EPS (₹) | 5.17 | 6.81 | 3.61 | 4.34 | 3.02 | - | - |
| Operating Margin (%) | 28.0% | 32.0% | 24.0% | 24.0% | 24.0% | - | - |
LAURUSLABS Share Price Trend — 1-Year Movement Across Quarterly Results
Laurus Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check LAURUSLABS company valuation to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
LAURUSLABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Laurus Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹421,995.00 Cr | 1758.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 155.6 |
|
Divis Laboratories
Mar 2026 |
₹241,231.30 Cr | 9162.0 | 2,986 | 751 | -5.0% | - | 25.2% | 323.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4615.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 401.0 |
|
Zydus Life Science
Mar 2026 |
₹111,111.95 Cr | 1135.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 89.7 |
|
Cipla
Mar 2026 |
₹106,152.60 Cr | 1330.9 | 6,612 | 543 | -9.3% | - | 8.2% | 193.7 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores